Recently, we reported that a cytosolic isoform of proteintyrosine phosphatase e (PTPeC), when overexpressed, inhibits terminal differentiation and apoptosis of murine M1 myeloblastic leukemia cells induced by interleukin-6. To determine whether these observed effects in vitro correspond to a tumorigenicity of PTPeC-expresser (M1-eC) cells in vivo, parent M1 and M1-eC cells were intravenously inoculated into scid or nude mice, and survival of mice receiving these cell lines was monitored. Unexpectedly, both scid and nude mice inoculated with M1-eC cells showed significantly prolonged survival time than those receiving parent M1 cells. While parent M1 cells inoculated by intravenous injection formed metastatic tumors in the spleen, expression of PTPeC suppressed tumor development in the spleen. The results suggest a suppressive role of PTPeC in tumorigenesis.
Recently, we reported that a cytosolic isoform of proteintyrosine phosphatase e (PTPeC), when overexpressed, inhibits terminal differentiation and apoptosis of murine M1 myeloblastic leukemia cells induced by interleukin-6. To determine whether these observed effects in vitro correspond to a tumorigenicity of PTPeC-expresser (M1-eC) cells in vivo, parent M1 and M1-eC cells were intravenously inoculated into scid or nude mice, and survival of mice receiving these cell lines was monitored. Unexpectedly, both scid and nude mice inoculated with M1-eC cells showed significantly prolonged survival time than those receiving parent M1 cells. While parent M1 cells inoculated by intravenous injection formed metastatic tumors in the spleen, expression of PTPeC suppressed tumor development in the spleen. The results suggest a suppressive role of PTPeC in tumorigenesis. Oncogene (2003 Oncogene ( ) 22, 1758 Oncogene ( -1762 Oncogene ( . doi:10.1038 Keywords: PTP; PTPe; tumorigenicity; M1 Reversible phosphorylation of proteins on tyrosine residue plays a crucial role in regulating cellular proliferation, differentiation and malignant transformation. The levels of tyrosine phosphorylation of protein are governed by coordinated and competing actions of protein-tyrosine kinases (PTKs) and protein-tyrosine phosphatases (PTPs) (Hunter and Cooper, 1985; Fischer et al., 1991; Neel and Tonks, 1997) . Since many viral and cellular oncogenes are PTKs, PTPs are expected to have tumor-suppressive properties. Along these lines, it has been reported that several PTPs, indeed, antagonize the signaling initiated by oncogenic kinases and thereby suppress transformed-phenotypes. PTP-1B has been reported to antagonize the action of Bcr-Abl oncoprotein (LaMontagne et al., 1998a, b ). An isoform of T cell-PTP directly dephosphorylates and inactivates a mutant FGF receptor, which signals constitutively, and thereby suppresses tumorigenicity of glioblastoma cells (Klingler-Hoffmann et al., 2001) . A transmembrane PTP, LAR, can specifically suppress the activity of Ret-MEN2A, an oncogenic PTK (Qiao et al., 2001) . In addition, expression of some PTPs has been found to be downregulated in transformed cell lines and tumors although the significance of such reduction of PTPs expression, in most cases, remains elusive so far (Urushibara et al., 1998; Warabi et al., 2000; McArdle et al., 2001) . In contrast, some PTPs such as PTPa and Cdc25 appear to have cell-transforming activity (Zheng et al., 1992) .
Like PTKs, PTPs are structurally subgrouped into receptor-like, transmembranal PTPs and nontransmembranal PTPs. In this context, PTPe, a member of PTP family, has somewhat unique property. As a result from combination of alternative promoter usage, internal translation initiation, and post-translational proteolytic cleavage, the PTPe gene gives rise to four proteins; one transmembranal (PTPeM/tm-PTPe) and three cytoplasmic enzymes (PTPeC/cyt-PTPe, p67 and p65) (Elson and Leder, 1995; Nakamura et al., 1996; Tanuma et al., 1999; Gil-Henn et al., 2000 Peretz et al., 2000) . Among these, PTPeM/tm-PTPe and PTPeC/cyt-PTPe are the main isoforms. Each PTPe isoform shows unique cell type-specific expression pattern, subcellular localization and presumably physiological functions (Elson and Leder, 1995; Tanuma et al., 2000; Andersen et al., 2001) . PTPeM/tm-PTPe is specifically overexpressed in murine mammary tumors initiated by ras or neu (Elson and Leder, 1995) . Previous studies have suggested that PTPeM increases the risk of mammary hyperplasia and mammary tumors (Elson, 1999) . In hematopoietic cells, a major isoform expressed is a cytosolic PTPeC/ cyt-PTPe but less is known about the roles of this isoform in tumorigenesis. Recently, we reported that PTPeC, when overexpressed, inhibits terminal differentiation and apoptosis of murine M1 myeloblastic leukemia cells induced by interleukin-6 (Tanuma et al., 2000 (Tanuma et al., , 2001 . The results prompted us to examine whether such observed effects in vitro correspond to a tumorigenicity of PTPeC-expresser (M1-eC) cells in vivo.
First, we examined the effects of PTPeC expression on growth characteristics of M1 cells in vitro. The mocktransfected M1-neo cells and M1 clones expressing PTPeC (M1-eC cells) or PTPeC-DA (M1-eC-DA) were cultured in the presence or absence of IL-6 or IFN-g, and the numbers of viable cells were determined by Trypan blue dye exclusion. PTPeC-DA is a mutant of PTPeC that carries an Ala substitution of invariant Asp residue within its catalytic domain, and is catalytically inactive. Under standard culture conditions (i.e. in the absence of IL-6 or IFN-g), growth kinetics of these clones was similar (Figure 1) . The doubling-time estimated was 16.8, 17.5 and 18 h for M1-neo, M1-eC and M1-eC-DA cells, respectively. Also, these clones exhibited similar serum dependence to proliferate in the medium (data not shown). As previously reported, IL-6 induced growth arrest and subsequent death in M1-neo cells (Tanuma et al., 2000) . In contrast to M1-neo and M1-eC-DA cells, M1-eC cells continued to proliferate at least up to 3 days even in the presence of IL-6 (Figure 1) . These are consistent with our previous report that PTPeC confers resistance to IL-6-induced differentiation and apoptosis in M1 cells (Tanuma et al., 2000) . Growth of M1-neo, M1-eC and M1-eC-DA cells in the presence of IFN-g was also investigated since IFN-g has been reported to cause growth arrest in M1 cells (Hoffman and Liebermann, 1991) . Apparently, M1 cells used in our study had relatively less potency to respond to IFNg. IFN-g only slightly decreased proliferation of M1-neo cells, whereas M1-eC cells were mostly resistant to the IFN-g-mediated growth suppression (Figure 1a) . To see the effects of PTPeC on tyrosine phosphorylation of cellular proteins, we immunoblotted M1-neo, M1-eC and M1-eC-DA cell lysates before and after IL-6 stimulation with anti-phosphotyrosine antibody (Figure 1b) . IL-6 induced two bands at the size of about 130 and 65 kDa in M1-neo cells. The upper band appears to correspond to gp130 and/or JAKs while the lower one is not known. In the case of M1-eC cells, the intensity of these two bands was reduced compared with the same bands from control M1-neo and M1-eC-DA cells. The intensity of the other bands was essentially similar among M1-clones.
M1 cells are tumorigenic when injected into syngeneic or immunodeficient mice (Lord et al., 1993; Krishnaraju et al., 1998; Smith et al., 2000) . When parent M1 cells were intravenously injected into nude or C.B-17 scid Figure 1 Growth characteristics of M1-PTPeC cells in vitro. (a) Proliferation curve of cells in the RPMI1640 medium with 10% fetal calf serum without (circles) or with 10 ng/ml of IL-6 (squares), or 1000 U/ml of IFN-g (triangles). Establishment and culture of M1 clones stably expressing PTPeC (M1-eC) or its mutant, PTPeC-DA (M1-eC-DA) has been described elsewhere (Tanuma et al., 2000) . (Figure 2b) . In contrast, expression of PTPeC-DA did not affect the survival of mice (Figure 2b) .
We found that the intravenously inoculated M1 cells formed metastatic foci mainly in the spleen both in scid and nude mice. Since the spleen in scid mice is much smaller compared with those in other strains including nude mice, we considered that scid mice have an advantage to examine the growth of metastatic cells at this site. Therefore, we employed scid mice for further analyses. As shown in Figure 3a and c, the spleen of scid mice intravenously injected with parent M1 cells slightly increased in size and weight when compared to those of control mice at day 18. In the spleen of mice receiving parent M1 cells, multiple metastatic foci were found at day 18 (Figure 3a) . The metastatic foci continued to grow and occupied almost the whole region of the spleen at day 23, resulting in marked enlargement of the spleen (Figure 3a and b) . In a striking contrast, tumor development of M1-eC was delayed when compared to parent cells (Figure 3) . However, this suppression by PTPeC was apparently incomplete because the mice that received M1-eC cells eventually showed enlarged spleen occupied with tumor cells at death. Expression of the mutant PTPeC, PTPeC-DA, had little or no effect on the growth of M1 cells in the spleen. With microscopic examination, we found that the number of metastatic foci was greatly reduced in the spleen of mice receiving M1-eC cells at day 23 when compared with mice receiving parent M1 cells at day 18 (data not shown). These results suggest that PTPeC suppresses proliferation of metastasized cells at relatively early phase of tumor development, or the metastasis itself. Although tumors were still observed upon injection of the stably transfected population of M1-eC cells, it is possible that these tumors were derived from subclones of the cells that had lost expression of PTPeCtransgenes.
Previous studies have suggested that PTPeM/tm-PTPe increases the risk of mammary hyperplasia and mammary tumors (Elson, 1999) . This study focused on the role for another PTPe isoform, PTPeC, in the tumorigenicity of cells of hematopoietic origin. PTPeC reduced tumorigenicity of M1 cells and prolonged survival of the mice. This is the first report to demonstrate a tumor-suppressive effect in vivo of PTPe expression in leukemic cells. The differences between functions of PTPe isoforms in tumorigenesis may be attributable to differences in the origin of tumor and/or differences in their subcellular loci and hence substrates of PTPe isoforms.
Since the expression of a catalytically inactive mutant, PTPeC-DA, neither affects in vivo growth of M1 cells nor mice survival, the PTPeC-mediated suppression of tumorigenicity depends on its PTPase activity. Given that PTPeC confers resistance to antiproliferative effects of IL-6 and IFN-g in vitro, the reduced tumorigenicity of M1 cells expressing PTPeC in mice was somewhat surprising because tumorigenicity of M1 cells and their derivatives has been often correlated with their proliferation and differentiation characteristics in vitro (Lord et al., 1993; Krishnaraju et al., 1998; Smith et al., 2000) . However, our results demonstrated tumor-suppressive role for PTPeC, which could not be observed in vitro. Of course, it is possible that PTPeC would antagonize with the tumor-suppressive activities of IL-6 and IFN-g in our experimental model if mice were challenged with IL-6 and IFN-g. Precise mechanism whereby PTPeC antagonizes tumorigenicity of M1 cells remains unknown at present. One explanation is that under conditions of cell growth in vivo, PTPeC may suppress proliferation by modulating intracellular signaling in response to growth factor(s) and/ or cytokine(s), or by promoting cell death. Also, it is possible that PTPeC affects the metastatic ability of tumor cells. Further studies to elucidate whether PTPeC affects either metastasis or cell proliferation in vivo, and identification of substrate will enable us to fully understand how tumorigenesis is regulated. 
